CD38 PET scan for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study uses a special PET scan that looks for a protein called CD38 on myeloma cells to see if it can better find and track multiple myeloma compared to the standard PET scan. It might help doctors plan your treatment more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple myeloma, or it is suspected to have come back or spread.
- You are already scheduled to have both a standard PET/CT scan and this special CD38 PET/CT scan.
- You are able to give written permission to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
This study uses a special PET/MR scan with a tracer called 68Ga-Pentixafor to see if it can better find lymphoma and multiple myeloma spots in the body. It may help doctors get clearer pictures than standard scans.
This study tests a new imaging agent that may help doctors see multiple myeloma more clearly. It uses a special radioactive tracer that targets a protein found on myeloma cells, which could improve diagnosis and monitoring of the disease.
Hear when a new Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.